Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Camilleri

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
BMJ Case Reports|January 14, 2012
Chemotherapy induced HyponatraemiaKheng-Wei Yeoh, Philip Camilleri, Kinnari Patel
Cureus|June 21, 2021
Implementation of Stereotactic MRI-Guided Adaptive Radiotherapy (SMART) for Hepatobiliary and Pancreatic Cancers in the United Kingdom - Fifty in FiveAndrew Gaya, Philip Camilleri, Adam Nash, et al.
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|July 30, 2022
Based on 0.35 T magnetic resonance-guided radiotherapy, what are the nonisotropic PTV margins required for conventional prostate radiotherapy?Joseph Drabble, Prantik Das, Ben George, et al.
Nature Reviews. Urology|May 3, 2020
Harnessing the potential of multimodal radiotherapy in prostate cancerYiannis Philippou, Hanna Sjoberg, Alastair D Lamb, et al.
Cancers|August 10, 2024
The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC)Elena Moreno-Olmedo, Ami Sabharwal, Prantik Das, et al.
Advances in Radiation Oncology|September 3, 2024
Stereotactic Magnetic Resonance-Guided Daily Adaptive Radiation Therapy for Localized Prostate Cancer: Acute and Late Patient-Reported Toxicity OutcomesKillian Nugent, Prantik Das, Dan Ford, et al.
Technical Innovations & Patient Support in Radiation Oncology|March 5, 2020
Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomesRosie Cooke, Philip Camilleri, Kwun-Ye Chu, et al.
Brachytherapy|August 21, 2010
Prostatic length predicts functional outcomes after iodine-125 prostate brachytherapyRaj P Pal, Jaimin R Bhatt, Masood A Khan, et al.
Cancer Medicine|September 6, 2019
ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE studyLennard Y W Lee, Thomas Starkey, Shivan Sivakumar, et al.
BMC Cancer|September 30, 2023
A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT)Sydney Wolfe, Marshall A Diven, Ariel E Marciscano, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
BMJ Case Reports|January 14, 2012
Chemotherapy induced HyponatraemiaKheng-Wei Yeoh, Philip Camilleri, Kinnari Patel
Cureus|June 21, 2021
Implementation of Stereotactic MRI-Guided Adaptive Radiotherapy (SMART) for Hepatobiliary and Pancreatic Cancers in the United Kingdom - Fifty in FiveAndrew Gaya, Philip Camilleri, Adam Nash, et al.
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|July 30, 2022
Based on 0.35 T magnetic resonance-guided radiotherapy, what are the nonisotropic PTV margins required for conventional prostate radiotherapy?Joseph Drabble, Prantik Das, Ben George, et al.
Nature Reviews. Urology|May 3, 2020
Harnessing the potential of multimodal radiotherapy in prostate cancerYiannis Philippou, Hanna Sjoberg, Alastair D Lamb, et al.
Cancers|August 10, 2024
The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC)Elena Moreno-Olmedo, Ami Sabharwal, Prantik Das, et al.
Advances in Radiation Oncology|September 3, 2024
Stereotactic Magnetic Resonance-Guided Daily Adaptive Radiation Therapy for Localized Prostate Cancer: Acute and Late Patient-Reported Toxicity OutcomesKillian Nugent, Prantik Das, Dan Ford, et al.
Technical Innovations & Patient Support in Radiation Oncology|March 5, 2020
Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomesRosie Cooke, Philip Camilleri, Kwun-Ye Chu, et al.
Brachytherapy|August 21, 2010
Prostatic length predicts functional outcomes after iodine-125 prostate brachytherapyRaj P Pal, Jaimin R Bhatt, Masood A Khan, et al.
Cancer Medicine|September 6, 2019
ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE studyLennard Y W Lee, Thomas Starkey, Shivan Sivakumar, et al.
BMC Cancer|September 30, 2023
A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT)Sydney Wolfe, Marshall A Diven, Ariel E Marciscano, et al.
Pageof 2